

I. The Office Action

The December 14, 2006 office action (the "Office Action") in this application:

- 1.) rejects claims 1, 4, 6, 8-10, 12-15, 18-20, 32 and 33 under 35 U.S.C. 112, first paragraph; and
- 2.) allows claims 11, 34 and 35.

Applicants respond as follows.

II. Cancelled claims

Claims 1, 4, 6, 8-10, 12-15, 18-20 and 32-33 are hereby cancelled, without prejudice of disclaimer, to further prosecution at a later date in related continuation application(s).

III. Rejection of claims 1, 4, 6, 8-10, 12-15, 18-20, 32 and 33 under 35 U.S.C. 112, first paragraph

The Office Action has rejected claims 1, 4, 6, 8-10, 12-15, 18-20, 32 and 33 under 35 U.S.C. 112, first paragraph because the specification, while being enabling for a method of for treating a mammary gland disorder with Clostridial neurotoxin botulinum toxin A and Clostridial difficile toxin A, does not reasonably provide enablement for treating a mammary gland disorder with any Clostridial neurotoxin or preventing development of a mammary gland neoplasm/carcinoma. Applicants traverse this rejection.

The above referenced claims are hereby cancelled with out prejudice or disclaimer, without conceding to the correctness of the rejections made in the Office Action, solely to further prosecution of the instant case.

Thus, this rejection should be withdrawn.

IV. Conclusion

All issues raised in the Office Action have been addressed. Only allowed claims 11, 34-35 remain pending in the case. Accordingly, a notice of allowance to that effect is respectfully solicited.

Should any matter(s) remain unresolved, the Examiner is invited to call Claude L. Nassif at the number below.

The Commissioner is hereby authorized to charge any fee(s) required or necessary for the filing, processing or entering of this paper or any of the enclosed papers and to refund any overpayment to deposit account 01-0885.

Respectfully submitted,

/CLAUDE L. NASSIF/

Date: February 16, 2007

---

Claude L. Nassif, Ph.D., Reg. No. 52,061

Address all inquiries and correspondence to:

Claude L. Nassif, Ph.D.  
Allergan, Inc., Legal Department  
2525 Dupont Drive  
Irvine, CA 92612  
Telephone: 714.246.6458  
Fax: 714.246.4249